Visit our website:
http://www.france24.com
Like us on Facebook:
https://www.facebook.com/FRANCE24.English
Follow us on Twitter:
https://twitter.com/France24_en
Category
🗞
NewsTranscript
00:00Now you are the head of the Epidemiology and Global Health Division at the National Institute
00:04of Biomedical Research in the DRC, which is of course the epicentre of this outbreak.
00:08How does this outbreak in your opinion compare to past outbreaks of Mpox?
00:16Thank you so much for this opportunity to talk to people regarding Mpox. So I think the
00:24current outbreak is really important compared to the past outbreak, as we see a huge
00:34increase in the number of cases since 2023. And also the new dynamic of transmission that
00:41we are seeing, we knew that Mpox was a zoonotic disease, so most animals to human transmission
00:50and less human to human transmission. And now we are seeing a kind of sustained human to human
00:56transmission and even with subglades that can be transmitted through sexual activities.
01:04And how deadly is Mpox for those who contract it compared to say COVID-19?
01:10Now, I can say that the global mortality of Mpox in the DRC is about 3.6%. So, and I can say that
01:28the burden is mostly among children under 15. And also, we see some comorbidities
01:37in children under 10, under 5, for example. Yeah.
01:47And how effective is the vaccine in combating this latest strain of Mpox? We've been reading
01:54so much about the 1B, the clade 1B variant that was detected, a first case of which was detected
02:00in Sweden just five days ago. How effective is the vaccine in combating this strain,
02:05this latest strain of Mpox? For the moment, we don't know exactly how effective can be the
02:14vaccine. We know that the vaccine can provide a good immunogenicity, but there is no, in my
02:23knowledge, a study done to assess the effectiveness of efficacy of the vaccine in our context. So,
02:32we don't know, but we suppose that if the vaccine was designed for the Mpox in general,
02:41it should be effective against also the clade 1B. But as I can say, we are not sure 100%.
02:51And what then are the main challenges when it comes to vaccine access in Africa? And also
02:56crucially, how much enthusiasm is there among the general population for a new Mpox vaccine?
03:03I think the challenge is first the number of doses available. I think for the whole continent,
03:12we estimate about maybe 10 million of vaccine doses. But it seems like in the pipeline,
03:21there are maybe around like 500,000 doses that could be available through donation from partners
03:29and so on. So, we think that it's not enough and we need to work more and the countries need to
03:40also be really involved to see how we can get more vaccine for the population. As we know that
03:46after the cessation of smallpox vaccination, all people born after the cessation of smallpox
03:55vaccination are susceptible to get this Mpox. So, we need as we are working to prevent and
04:04get the vaccine, but we need also to see how we can also improve case management.
04:12Plessy Dumbala, Associate Professor at the University of Kinshasa School of Medicine.
04:15Thank you so much for speaking to us today.